This is a summary of the European public assessment report (EPAR) for Relistor. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Relistor.
For practical information about using Relistor, patients should read the package leaflet or contact their doctor or pharmacist.
Relistor : EPAR - Summary for the public (PDF/82.86 KB)
First published: 10/07/2008
Last updated: 06/02/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
PharmaSwiss Ceska Republika s.r.o
|Date of issue of marketing authorisation valid throughout the European Union||
19/12/2018 Relistor - EMEA/H/C/000870 - N/0048
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.